Monitoring glucose levels in critically ill patients
Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients
This study looks at how often critically ill patients in the ICU experience low blood sugar and how using continuous glucose monitors can help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 245 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universidad Europea de Madrid Academic / other |
| Locations | 1 site (Madrid) |
| Trial ID | NCT06234787 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence of hypoglycemic events in critically ill patients admitted to the ICU at HLA Moncloa Hospital over a four-year period. It will document occurrences of low glucose levels detected by continuous subcutaneous glucose monitoring (CGM) and describe the characteristics of patients receiving CGM sensors. The study seeks to understand the impact of glycemic control on patient outcomes and the actions taken in response to detected hypoglycemic events.
Who should consider this trial
Good fit: Ideal candidates include critically ill patients in the ICU who are undergoing insulin treatment and have a CGM sensor.
Not a fit: Patients who are not admitted to the ICU or those who cannot provide information on CGM due to technical issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve glycemic management in critically ill patients, potentially reducing the incidence of hypoglycemic events and associated complications.
How similar studies have performed: Other studies have shown varying success with continuous glucose monitoring in critical care settings, indicating potential benefits but also highlighting the complexity of glycemic management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor. * Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised. Exclusion Criteria: * Patients from whom information on CGM cannot be obtained for technical reasons.
Where this trial is running
Madrid
- Hospital Universitario HLA Moncloa — Madrid, Spain (Recruiting)
Study contacts
- Study coordinator: Samuel G González, Doctor
- Email: samuelgonlop@gmail.com
- Phone: 34692619904
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.